Processing...
All Trials
Search
Search
There are 1659 active trials in our database.
Click on a trial to see more information.
1659 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced/metastatic solid tumors after standard therapy receive REGN10597, an intravenously delivered anti–PD-1–IL2RA–IL2 fusion protein designed to target IL-2 signaling to PD-1–positive activated T cells while limiting systemic IL-2 effects; expansion cohorts enroll melanoma and clear-cell RCC. Key exclusions include prior IL-2/IL-15/IL-7 therapy, recent checkpoint inhibitors or systemic therapy, active immune-related AEs, significant autoimmune disease, or need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06413680
TrialFetch AI summary: Adults with CLDN6-positive advanced solid tumors—emphasizing platinum-resistant/refractory ovarian cancer (also endometrial or testicular)—with measurable disease and ECOG 0–2 receive weekly IV CTIM-76, a CLDN6×CD3 T cell–engaging bispecific antibody, in dose escalation and expansion cohorts. Excludes active/untreated CNS disease, prior CLDN6 therapy, uncontrolled infection; treatment continues until progression or toxicity.
ClinicalTrials.gov ID: NCT06515613
TrialFetch AI summary: Adults (≥18; ≥15 for germ cell tumors) with CLDN6-positive advanced ovarian/fallopian tube/primary peritoneal cancer, endometrial adenocarcinoma, or germ cell tumors after standard therapy receive XmAb541, an investigational CLDN6×CD3 bispecific T‑cell–engaging antibody given IV or SC with step-up dosing. Excludes prior CLDN6-directed therapy, platinum-refractory ovarian cancer or rapid progression on ≥2nd-line, uncontrolled CNS metastases, active autoimmune disease, and significant comorbidities.
ClinicalTrials.gov ID: NCT06276491
TrialFetch AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.
ClinicalTrials.gov ID: NCT03968406
TrialFetch AI summary: Adults with recurrent gynecologic cancers—platinum-resistant high‑grade serous ovarian/fallopian tube/primary peritoneal, selected endometrial, and cervical cancers—receive IMGN151, an investigational FRα‑targeted antibody–drug conjugate (biparatopic anti‑FRα linked to maytansinoid DM21) given IV every 3 weeks. Expansion includes cohorts with/without prior FRα therapy (where allowed), with requirements such as measurable disease and prior checkpoint inhibitor use in eligible endometrial and cervical cancer.
ClinicalTrials.gov ID: NCT05527184
TrialFetch AI summary: Adults with locally advanced/metastatic solid tumors (ECOG 0–1) who have progressed on prior therapy and lack standard options receive SPX‑303 monotherapy, a first‑in‑class bispecific antibody targeting LILRB2 (ILT4) on myeloid cells and PD‑L1, given IV every 3 weeks. Excludes active/unstable CNS disease and prior ILT2/ILT4/HLA‑G–targeted therapy; allows well-controlled HIV.
ClinicalTrials.gov ID: NCT06259552
TrialFetch AI summary: Adults with untreated recurrent/metastatic HNSCC (non‑nasopharyngeal) eligible for pembrolizumab are randomized to pembrolizumab alone versus pembrolizumab plus BI 770371 (anti‑SIRPα blocking the CD47–SIRPα “don’t‑eat‑me” axis) with or without cetuximab (anti‑EGFR). Prior definitive therapy is allowed if >6 months from progression; requires measurable disease and tumor tissue, and excludes prior PD‑(L)1 or SIRPα/CD47 agents and active brain metastases.
ClinicalTrials.gov ID: NCT06806852
TrialFetch AI summary: Adults with recurrent/metastatic, incurable HNSCC requiring palliative RT and having two index lesions (one for RT, one for serial biopsy) receive pembrolizumab plus the investigational oral AXL/MerTK (TAM) inhibitor INCB081776, with RT delivered to one lesion excluded from efficacy assessments. Suitable for patients recovered from prior therapies, without autoimmune disease requiring immunosuppression or significant retinal disorders.
ClinicalTrials.gov ID: NCT06308913
TrialFetch AI summary: Metastatic, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (initially platinum-sensitive; ≤1 prior line for platinum-resistant disease; prior PARP allowed) treated with PLX038, a long-acting pegylated prodrug of SN-38 (topoisomerase I inhibitor) given IV every 21 days until progression/toxicity. Excludes non–HGS histology and patients with UGT1A1 deficiency (e.g., Gilbert’s or homozygous UGT1A1*28).
ClinicalTrials.gov ID: NCT05465941
TrialFetch AI summary: Adults with recurrent, platinum-resistant epithelial ovarian cancer whose tumors are TAG72-positive receive lymphodepleting fludarabine/cyclophosphamide followed by a single intraperitoneal infusion of autologous TAG72-directed CAR T cells. Investigational therapy targets the TAG72 glycoprotein to mediate CAR T–cell killing of peritoneal ovarian cancer; single-arm dose-escalation with long-term follow-up.
ClinicalTrials.gov ID: NCT05225363